Atezolizumab

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4491 publications

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Journal: JAMA network open
Published: April 15, 2026

Comparative pharmacovigilance signals for PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in the FAERS database.

Comparative pharmacovigilance signals for PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in the FAERS database.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: April 13, 2026

Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context.

Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context.

Journal: Cancer investigation
Published: April 10, 2026

Subcutaneous atezolizumab for the treatment of non-small cell lung cancer.

Subcutaneous atezolizumab for the treatment of non-small cell lung cancer.

Journal: Therapeutic delivery
Published: April 07, 2026

A high-throughput selection system for fast-acting covalent protein drugs.

A high-throughput selection system for fast-acting covalent protein drugs.

Journal: Science (New York, N.Y.)
Published: April 02, 2026

Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer.

Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer.

Journal: JAMA otolaryngology-- head & neck surgery
Published: April 02, 2026

National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia.

National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia.

Journal: Expert review of anticancer therapy
Published: April 01, 2026

A Case of Combined Small Cell Lung Carcinoma with a Rhabdomyosarcomatous Component Diagnosed by a Thoracoscopic Biopsy and Treated with Chemoimmunotherapy.

A Case of Combined Small Cell Lung Carcinoma with a Rhabdomyosarcomatous Component Diagnosed by a Thoracoscopic Biopsy and Treated with Chemoimmunotherapy.

Journal: Internal medicine (Tokyo, Japan)
Published: April 01, 2026

Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report.

Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report.

Journal: Immunotherapy
Published: March 28, 2026

Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.

Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.

Journal: JCO oncology practice
Published: March 26, 2026

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

Journal: The New England journal of medicine
Published: March 25, 2026

Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Journal for immunotherapy of cancer
Published: March 16, 2026
Showing 1-12 of 4,491

Last Updated: 04/28/2026